Tag: Investigational New Drug
BioRay’s IND Application for BRY812, Accepted by the China National Medical...
The China National Medical Products Administration (NMPA) has accepted the Investigational New Drug (IND) application for BRY812, a novel antibody-drug conjugate (ADC) targeting human LIV-1 for the treatment of advanced malignant tumors (Acceptance No. CXSL2300366). The investigational drug is being developed by Shanghai-based BioRay Pharmaceutical Co.
Sutro Confirms IND for Second Cell-Free ADC Targeting Anti-Folate Receptor-α for...
Sutro Biopharma confirmed that the U.S. Food and Drug Administration (FDA) has concluded their 30-day review of the Investigational New Drug (IND) application for...
Antibody Drug Conjugate Development: Keys to Rapid IND Submission and Approval
Antibody drug conjugates (ADCs) are a relatively new type of drug that combines the targeting ability of a biologic with a highly potent cytotoxic...
U.S. FDA Accepts Investigational New Drug Application for Mersana’s Lead Antibody-Drug...
The U.S. Food and Drug Administration (FDA) cleared Mersana Therapeutics’ Investigational New Drug (IND) application to begin Phase I clinical trials for its lead...
